Cetuximab (2004) was first approved for the treatment of metastatic colorectal carcinoma (CRC) and head and neck squamous cell carcinoma (HNSCC), while avelumab (2017, NCT03089658) and amivantamab (2021, NCT04599712) were approved for the treatment of metastatic Merkel cell carcinoma and EGFR-mutant NSCLC, respectively. The gene discussed is EGFR; the disease is head and neck squamous cell carcinoma.